Polyrizon Ltd. Ordinary Shares (PLRZ)

FairStock Score: 37/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look at Polyrizon the way Graham would: first ask what is proven, then ask what I pay. Here, the business is a two-employee Israeli biotech developing nasal-spray hydrogels — Capture and Contain, Trap and Target, PL-14, PL-16. That is early-stage and unproven; I see no durable competitive moat in the provided numbers. The financials are weak: at the 2026-10-13 close of $9.74, the FairStock-calculated P/E is -1.96, so there are no positive earnings to value. P/B is 0.85, which might catch a bargain hunter’s eye, but a low price-to-book ratio without earning power is not automatically a bargain. FairStock’s ROE and ROCE are -21.42% and -23.30%, and the Piotroski F-Score is 0/9. The one supportive calculation is an Altman Z-Score of 36.69, suggesting low bankruptcy risk on that measure, though D/E is N/A. Growth is impossible to assess: revenue growth and profit growth are both N/A, and the Lynch category is none because there are only 0 years of filed results, versus the 3 needed. Market cap is $27.0M, FairStock Score 37/100. The 52-week range of $2.88 to $18.20 shows how speculative the quote has been. As a Buffett-style investor, I want an understandable, consistently profitable business with a moat and a margin of safety. Polyrizon may have promising science, but today it offers no demonstrated earnings, no filed growth history, and no clear moat. The price may look low against book value, but the business quality does not yet support a confident intrinsic-value case.

In plain English: Polyrizon is a tiny Israeli biotech with only two employees, working on nasal spray gels that aim to block allergens and viruses or deliver medicines. The business looks weak right now: it loses money, has no reported revenue or profit growth in the data, and its financial checklist score is very low. At $9.74, the price is hard to call cheap or expensive because there are no proven profits, but it looks speculative given the wide 52-week range of $2.88 to $18.20.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer